Human medicines European public assessment report (EPAR): Delstrigo, doravirine,lamivudine,tenofovir disoproxil, HIV Infections, Date of authorisation: 22/11/2018, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Ristfor, sitagliptin,metformin hydrochloride, Diabetes Mellitus, Type 2, Date of authorisation: 15/03/2010, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Efficib, sitagliptin,metformin, Diabetes Mellitus, Type 2, Date of authorisation: 15/07/2008, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Janumet, sitagliptin,metformin, Diabetes Mellitus, Type 2, Date of authorisation: 16/07/2008, Date of refusal: 18/02/2009, Revision: 30, Status: Authorised

Human medicines European public assessment report (EPAR): Fluad Tetra, influenza vaccine (surface antigen, inactivated, adjuvanted), Influenza, Human, Date of authorisation: 20/05/2020, Revision: 7, Status: Authorised

Declaration of interests: Patrice Verpillat

Orphan designation: Recombinant human factor IX protein modified with three point mutations (dalcinonacog alfa), Treatment of haemophilia B, 20/06/2017, Positive

Orphan designation: Marzeptacog alfa (activated), Treatment of haemophilia B, 01/04/2019, Positive

Victoza (liraglutide) supply shortage

Human medicines European public assessment report (EPAR): Brilique, ticagrelor, Peripheral Vascular Diseases;Acute Coronary Syndrome, Date of authorisation: 03/12/2010, Revision: 21, Status: Authorised